Home     About     Portfolio     News & Events     Contact

Our Investment Strategy


Cato BioVentures invests only in opportunities where we can make a difference in development or regulatory strategy. We often co-invest with other institutional investors and generally we do not require a Board seat as a condition of our investment. Still, in a Board-like manner, our principals regularly provide essential market, regulatory and drug development insights, as well as financial, operational and strategic advice, to portfolio company management through regular and uncompensated communications. We are long-term investors who can assist our portfolio companies with product development - including clinical development, regulatory affairs, manufacturing, government and private foundation grant-writing - and corporate development - including corporate finance, strategic planning and corporate partnering.

We value the opportunity to work closely with management in multiple areas to build value in our portfolio partners' drug or technology development opportunities. Typically, we deploy the collective development and regulatory expertise of our principals and the entire 300+ person CRO staff of Cato Research to achieve maximum value for our partners. Drug development, including preclinical studies, clinical studies, manufacturing, and regulatory affairs, have been the core components of the business of Cato Research for over 30 years.


Management

Allen Cato, M.D., Ph.D.

Principal

Allen Cato, PrincipalDr. Cato is a principal and cofounder of Cato BioVentures. He also is a cofounder of Cato Research and serves as its CEO and director. Dr. Cato serves as a member of the clinical advisory board of VistaGen Therapeutics and in senior management or director roles for several of our portfolio companies, past and present, including but not limited to, Advanced Pain Remedies, Cancer Advances, Hemodynamic Therapeutics and Nutritional Restart Pharmaceuticals. He has 40 years' experience in clinical research and new drug development and has directed or participated in the development of more than 100 INDs and NDAs.

Lynda Sutton, B.S.

Principal

Lynda Sutton, PrincipalMs. Sutton is a principal and cofounder of Cato BioVentures. She also is a cofounder of Cato Research and serves as President and its' chief regulatory officer. Ms. Sutton serves in senior management and director roles for several of our portfolio companies, past and present, including but not limited to, Advanced Pain Remedies, Cancer Advances, Hemodynamic Therapeutics and Nutritional Restart Pharmaceuticals. She has more than 30 years' experience in the pharmaceutical industry, with special expertise in regulatory strategies and regulatory compliance requirements. She has coordinated activities in various disciplines (e.g., toxicology, pharmacology, pharmacokinetics, analytical and pharmaceutical development, and clinical research), has been involved in the development of new clinical entities, has overseen the preparation of FDA meeting submissions, and has ensured that regulatory requirements necessary for the approval and launch of new products have been satisfied.

Daniel Pharand, C.P.A., C.A.

Principal

Cato Bioventures - Daniel PharandMr. Pharand is a chartered accountant with more than 25 years' experience in the pharmaceutical, biotechnology, and life sciences industries, where he has a proven track record as a portfolio manager. He serves as a principal of Cato BioVentures and as chief financial officer of Cato Research. Mr. Pharand was the CFO of Pharmacia Canada and of Pharmacia KK (Japan). He subsequently became an entrepreneur with a successful Canadian distribution company of innovative pedicular screw systems in orthopedic therapies. Mr. Pharand later was involved, as a portfolio manager, in a biotech venture with Innovatech Grand Montreal. Mr. Pharand has also acted as a director, including holding seats on various board committees for more than 30 publicly traded or life sciences corporations.

 

Investment Team

 

Eric M. Nelson, Ph.D.

Strategic Business Developer

Cato Bioventures - Eric M. NelsonEric Nelson, Ph.D. currently serves as Strategic Business Developer for Cato BioVentures. Broadly experienced, R&D strategic partnerships business development professional. Background at Wyeth/Pfizer, Becton Dickinson, and Elan/Athena Neurosciences. Have closed on over 50 biotechnology drug development partnerships worth over $1B. As an entrepreneur have helped build 4 biotechnology companies in US and Europe from start-up through successful IPO or acquisition exits. Helped the NIH start its very successful rare diseases drug discovery program (2010-2013). Therapeutic areas of expertise are oncology, inflammation/musculoskeletal/pain, respiratory, neurology, genetic and Orphan diseases.